Screener
Neurocrine Biosciences NBIX Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | March 31,2026 | December 31,2025 |
|---|---|---|
| Other noncurrent liabilities | 260.9 | 219.7 |
| Total liabilities | 1,498.8 | 1,378.4 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 220.0 shares authorized; 100.6 and 100.1 shares issued and outstanding, respectively | 0.1 | 0.1 |
| Additional paid-in capital | 2,817.3 | 2,792.2 |
| Accumulated other comprehensive income | 0.4 | 13.1 |
| Retained earnings | 589.6 | 447.7 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's preferred stock, shares authorized?
- Neurocrine Biosciences (NBIX) reported preferred stock, shares authorized of $5M in Q1 2026.
- How has Neurocrine Biosciences's preferred stock, shares authorized changed year-over-year?
- Neurocrine Biosciences's preferred stock, shares authorized decreased by 0.0% year-over-year, from $5M to $5M.
- What is the long-term trend for Neurocrine Biosciences's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $5M to $5M.
Ask your AI about Neurocrine Biosciences's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude